MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Align Technology Revenue 2011-2026 | ALGN
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Align Technology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 B | 3.86 B | 3.73 B | 3.95 B | 2.47 B | 2.41 B | 1.97 B | 1.47 B | 1.08 B | 845 M | 762 M | 660 M | 560 M | 480 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4 B | 480 M | 2.02 B |
Quarterly Revenue Align Technology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 996 M | 1.01 B | 979 M | - | 978 M | 1.03 B | 997 M | - | 960 M | 1 B | 943 M | - | 890 M | 970 M | 973 M | - | 1.02 B | 1.01 B | 895 M | - | 734 M | 352 M | 1.99 M | - | 3.48 M | 3.46 M | 2.63 M | - | 2.23 M | 1.92 M | 2.18 M | - | 1.83 M | 1.44 M | 1.2 M | - | 279 M | 269 M | 239 M | - | 208 M | 209 M | 198 M | - | 190 M | 193 M | 181 M | - | 165 M | 164 M | 154 M | - | 136 M | 146 M | 135 M | - | 126 M | 120 M | 105 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 B | 1.2 M | 422 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ClearPoint Neuro
CLPT
|
37 M | $ 9.23 | -1.6 % | $ 261 M |  USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | USA |
 |
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.46 | - | $ 130 M |  France |
 |
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.07 | - | $ 1.63 B | USA |
 |
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | USA |
 |
FONAR Corporation
FONR
|
97.6 M | $ 18.6 | - | $ 122 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | USA |
 |
Bruker Corporation
BRKR
|
3.37 B | $ 36.66 | -0.22 % | $ 5.46 K | USA |
 |
Globus Medical
GMED
|
2.94 B | $ 90.0 | 1.58 % | $ 12.2 B | USA |
 |
Helius Medical Technologies
HSDT
|
644 K | $ 1.81 | -4.74 % | $ 1.1 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.25 | -0.64 % | $ 712 M | USA |
 |
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | USA |
 |
Inspire Medical Systems
INSP
|
912 M | $ 54.21 | 0.13 % | $ 1.59 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.77 | 0.16 % | $ 2.98 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.78 | -1.0 % | $ 370 M | USA |
 |
IRIDEX Corporation
IRIX
|
52.7 M | $ 1.01 | 1.85 % | $ 17.1 M | USA |
 |
LENSAR
LNSR
|
58.4 M | $ 5.82 | -1.27 % | $ 69.6 M | USA |
 |
Medtronic PLC
MDT
|
33.5 B | $ 86.12 | -0.19 % | $ 111 B | USA |
 |
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | USA |
 |
Myomo
MYO
|
40.9 M | $ 0.67 | -4.9 % | $ 28 M | USA |
 |
AxoGen
AXGN
|
225 M | $ 31.33 | -4.03 % | $ 1.44 B | USA |
 |
Orthofix Medical
OFIX
|
822 M | $ 11.58 | -1.61 % | $ 459 M |  Curacao |
 |
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | USA |
 |
Penumbra
PEN
|
1.4 B | $ 329.2 | -0.2 % | $ 12.8 B | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | USA |
 |
Insulet Corporation
PODD
|
2.71 B | $ 203.09 | -0.2 % | $ 14.3 B | USA |
 |
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M |  Canada |
 |
Sintx Technologies
SINT
|
1.02 M | $ 2.49 | -1.58 % | $ 6.91 M | USA |
 |
Butterfly Network
BFLY
|
82.1 M | $ 4.03 | -2.42 % | $ 853 M | USA |
 |
Smith & Nephew plc
SNN
|
4.56 B | $ 31.88 | -2.3 % | $ 23.8 B |  Britain |
 |
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | USA |
 |
Stryker Corporation
SYK
|
7.17 B | $ 331.18 | -0.34 % | $ 127 B | USA |
 |
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.59 | 0.69 % | $ 36.7 M | USA |
 |
Tactile Systems Technology
TCMD
|
330 M | $ 24.49 | -0.33 % | $ 560 M | USA |
 |
TELA Bio
TELA
|
80.3 M | $ 0.62 | -2.08 % | $ 29.1 M | USA |
 |
TransMedics Group
TMDX
|
605 M | $ 104.84 | 0.04 % | $ 3.56 B | USA |
 |
BIOLASE
BIOL
|
49.2 M | - | -13.19 % | $ 166 K | USA |
 |
Tandem Diabetes Care
TNDM
|
290 M | $ 19.55 | 1.98 % | $ 1.33 B | USA |
 |
Delcath Systems
DCTH
|
85.2 M | $ 9.61 | -0.98 % | $ 344 M | USA |
 |
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
20.1 B | $ 61.27 | -2.11 % | $ 90.7 B | USA |